Other Events ·
Abbott Laboratories announced on August 20, 2026, that it entered into agreements to resolve the Gill lawsuit and…
ABTAbbott Laboratories
Abbott Laboratories announced on August 20, 2026, that it entered into agreements to resolve the Gill lawsuit and necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants for an aggregate amount of approximately $670 million. This settlement avoids paying approximately $600 million representing the original $495 million judgment plus accrued interest. The agreements are a compromise of disputed claims and not an admission of liability. Following this resolution, approximately 1,700 lawsuits remain pending in federal and state courts involving claims on behalf of roughly 12,700 individual infants. Abbott operates as a global healthcare leader providing diagnostics, medical devices, nutritionals, and branded generic medicines.